Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) EBT (2020 - 2024)

Immuneering has reported EBT over the past 5 years, most recently at -$18.1 million for Q4 2024.

  • Quarterly results put EBT at -$18.1 million for Q4 2024, down 16.69% from a year ago — trailing twelve months through Dec 2024 was -$61.5 million (down 12.17% YoY), and the annual figure for FY2025 was -$56.3 million, up 8.36%.
  • EBT for Q4 2024 was -$18.1 million at Immuneering, down from -$14.7 million in the prior quarter.
  • Over the last five years, EBT for IMRX hit a ceiling of -$3.6 million in Q2 2020 and a floor of -$18.1 million in Q4 2024.
  • Median EBT over the past 5 years was -$12.8 million (2022), compared with a mean of -$11.3 million.
  • Biggest five-year swings in EBT: tumbled 121.62% in 2021 and later dropped 0.81% in 2023.
  • Immuneering's EBT stood at -$5.8 million in 2020, then plummeted by 88.02% to -$11.0 million in 2021, then dropped by 22.75% to -$13.5 million in 2022, then fell by 15.44% to -$15.5 million in 2023, then decreased by 16.69% to -$18.1 million in 2024.
  • The last three reported values for EBT were -$18.1 million (Q4 2024), -$14.7 million (Q3 2024), and -$14.1 million (Q2 2024) per Business Quant data.